Fig. 1From: Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialBest response and time under treatment (3D waterfall plot)Back to article page